<DOC>
	<DOCNO>NCT01375868</DOCNO>
	<brief_summary>Vaccines human papillomaviruses commercially available . One commercial vaccine contains antigens LR HPV type cause virtually case RRP . Clinical trial document safety immunogenicity vaccine well effectiveness prevention incident persistent infection vaccinal type well development lesion cause type . After vaccination antibody level increase dramatically high level antibody present blood still 6 year . Furthermore , neutralization antibody vaccinal antigen detect cervical mucus vaccinate woman . The preliminary data available show presence HPV-specific antibody oral cavity woman vaccination . The level antibody dependent time since vaccination .</brief_summary>
	<brief_title>Effect Vaccination Patients With Recurrent Respiratory Papillomatosis</brief_title>
	<detailed_description>In previous study document patient RRP level HPV-specific antibody low increase numerous surgery procedure . Therefore application vaccine patient RRP stimulate increase level antibody blood well presence virus-specific neutralization antibody surface upper aero digestive tract neutralize virus shed new papilloma way protect patient spread infection well facilitate decrease load infectious virus shed lesion . This possibly lead inhibition growth papillomatous lesion .</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients RRP sign inform consent form part study enrol . Patients experience severe side effect vaccination first second dose vaccinate third dose exclude study . Patients receive three dos within one year 30 day also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>recurrent respiratory papillomatosis</keyword>
	<keyword>antibody</keyword>
</DOC>